Lipum AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIPUM.ST research report →
Companywww.lipum.se
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116.
- CEO
- Ola Sandborgh
- IPO
- 2021
- Employees
- 5
- HQ
- Umeå, SE
Price Chart
Valuation
- Market Cap
- $304.40M
- P/E
- -4.26
- P/S
- 0.00
- P/B
- -64.19
- EV/EBITDA
- -4.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 641.22%
- ROIC
- 1357.68%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-71,526,000 · -28.84%
- EPS
- $-3.37 · -4.66%
- Op Income
- $-62,520,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $19.95
- 52W Low
- $8.56
- 50D MA
- $14.13
- 200D MA
- $13.63
- Beta
- 0.26
- Avg Volume
- 186.92K
Get TickerSpark's AI analysis on LIPUM.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LIPUM.ST Coverage
We haven't published any research on LIPUM.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIPUM.ST Report →